Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies

Critical Reviews in Oncogenesis
James J Morrow, Chand Khanna

Abstract

Osteosarcoma is the most common primary malignancy of bone, typically presenting in the first or second decade of life. Unfortunately, clinical outcomes for osteosarcoma patients have not substantially improved in over 30 years. This stagnation in therapeutic advances is perhaps explained by the genetic, epigenetic, and biological complexities of this rare tumor. In this review we provide a general background on the biology of osteosarcoma and the clinical status quo. We go on to enumerate the genetic and epigenetic defects identified in osteosarcoma. Finally, we discuss ongoing large-scale studies in the field and potential new therapies that are currently under investigation.

Citations

Apr 9, 2016·International Journal of Molecular Sciences·Atik Badshah ShaikhGe Zhang
Mar 30, 2017·Cell Cycle·Atul RanjanTomoo Iwakuma
Oct 8, 2016·Journal of Experimental & Clinical Cancer Research : CR·Baochang QiDahui Sun
Oct 3, 2018·Journal of Cellular Biochemistry·Tao XiaoLi-Hong Liu
Jul 5, 2019·Bioscience Reports·Jian ZhouYingquan Luo
Aug 9, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Hongliang YingDaliang Kong
Oct 5, 2019·Oncogene·Branden A SmeesterBranden S Moriarity
Mar 21, 2020·Cancer Biotherapy & Radiopharmaceuticals·Lei YangZhen Li
Apr 17, 2020·Cells·Katia ScotlandiMassimo Serra
Jun 27, 2020·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Stuart H Ralston
Jan 18, 2016·Veterinary Sciences·Jyotika VarshneySubbaya Subramanian
Feb 14, 2018·International Journal of Molecular Medicine·Qingbing MengMinqian Zheng
Jul 6, 2017·International Journal of Molecular Medicine·Xuanhe SongWeiliang Yang
Feb 9, 2019·Academic Pathology·Aldis H Petriceks, Darren Salmi
Mar 19, 2019·Frontiers in Endocrinology·Consolato SergiSong-Mei Liu
Aug 23, 2019·Molecular Medicine Reports·Junkui SunJianxiang Shi
Aug 12, 2018·Pharmaceutics·Riccardo FerraciniGiuseppe Perale
Jan 23, 2020·Oncology Letters·Judson Welber Veríssimo de AzevedoJosé Veríssimo Fernandes
Apr 26, 2017·Molecular Medicine Reports·Yong CaoHongbin Lu
Oct 17, 2018·Expert Review of Molecular Diagnostics·Claudia Maria HattingerMassimo Serra
Jan 23, 2020·Cancers·Miguel Mateu-SanzCristina Canal
Jul 10, 2020·Neuro-oncology Advances·Stephen LiLu Q Le
Oct 6, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Aparna NatarajanThangarajan Rajkumar
Jun 28, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J MorrowChand Khanna
Jan 13, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Soudeh Ghafouri-FardMohammad Taheri
Aug 24, 2020·Bone·Filomena de NigrisClaudio Napoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Medical and Pediatric Oncology
Rajaram NagarajanJohn P Perentesis
Neurosurgical Focus
Janet C LindseySteven C Clifford
Gastroentérologie Clinique Et Biologique
Jean Marc PhelipJean Pierre Zarski
© 2021 Meta ULC. All rights reserved